Twist Bioscience Corporation
TWST
NASDAQ·Healthcare·Biotechnology·Mkt cap $7.8B
$124.72
▼ -3.10%
P/E
-105.69
Mkt Cap
$7.8B
52-Wk Range
$23.30–$155.44
52-Week Range
$23.30 - $155.44
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 375.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary silicon chip-based DNA synthesis platform enabling superior cost and speed efficiency
- Scalable manufacturing technology with significant barriers to entry and replication
- Strategic partnerships with major pharmaceutical companies validating technology and driving adoption
- Diversified product portfolio spanning drug discovery, diagnostics, and emerging data storage markets
- First-mover advantage in synthetic DNA manufacturing with established intellectual property portfolio
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Stable outlook
Expanding adoption of synthetic biology in pharmaceutical R&D and personalized medicine
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Hot
+78.1% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying TWST right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 3, 2026
Reported EPS of -$0.56 vs -$0.51 consensus (-10.6% surprise). Revenue of $118.4M vs $114.5M expected (+3.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-10.6%
Revenue trend · last 8Q
—
—
+24%
+23%
+18%
+17%
+17%
+23%
Q3 24
Q4 24
Q1 24
Q2 25
Q3 25
Q4 25
Q1 25
Q3 26
$81.5M
$84.7M
$88.7M
$92.8M
$96.1M
$99.0M
$103.7M
$118.4M
Margins · last 8Q
Gross
52.8%
Operating
-30.6%
Profit
-29.6%
Wall Street consensus
7 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$107.00
▼ -14.2% vs $124.72
Latest: Guggenheim · Aug 24, 2026
1 analyst covering
vs Industry
How TWST stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related